Proactive immune tolerance induction is applied using an automated infusion pump with a pre-programmed protocol. It follows the same stepwise dosing scheme as conventional desensitization therapy used in patients who have experienced hypersensitivity reactions before. However, it is uniquely performed in patients without a prior history of hypersensitivity reactions, aiming to prevent sensitization itself.
Age
19–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients receiving paclitaxel and carboplatin chemotherapy for gynecologic malignancies.
Patients with no prior history of hypersensitivity reactions to paclitaxel or carboplatin.
Patients who are able to read and voluntarily provide written informed consent.
Aged 19 years or older.
You may not be if
Patients who do not wish to participate in this study voluntarily.
Patients who, in the opinion of the investigator, are unsuitable for participation in this clinical trial.